Drug–drug Interactions in Hospitalized Cardiac Patients by Mateti, UV et al.
Journal of Young Pharmacists Vol 3 / No 4  329
Pharmacy Practice
thus: “two or more drugs interacting in such a manner 
that the effectiveness or toxicity of one or more drugs is 
altered”.[2‑5] DDI in patients receiving multidrug therapy is 
a major concern. Such interactions may lead to an increased 
risk of hospitalization and higher health care costs.[6] 
The incidence of actual occurrence of drug interactions 
has been reported to be much smaller, ranging from 0 
to 1.3%.[7,8] Some studies have found that up to 11% of 
patients experience symptoms associated with DDIs and 
that DDIs are responsible for up to 2.8% of hospital 
admissions.[9,10] Research has also shown that DDIs are 
associated with increased health care use.[11] According to 
a recently published study, 1% of all hospital admissions 
are caused by DDIs, and 0.05% emergency department 
visits, 0.6% of the hospital admissions and 0.1% of 
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re‑hospitalizations are caused by adverse drug reactions 
(ADRs) due to DDIs.[12,13]
The incidence of cardiovascular diseases (CVDs) has 
increased in recent decades. It has been estimated that 
CVDs are the most common cause of death in India and 
as a result cardiovascular drugs have moved to the second 
place among all drug classes prescribed in the country.[14] 
Patients with cardiovascular diseases are particularly 
vulnerable to DDIs due to their advanced age, polypharmacy 
and the influence of heart disease on drug metabolism. The 
DDI potential for a particular cardiovascular drug varies 
with the individual, the disease being treated, and the extent 
of exposure to other drugs.[15]
Potential for drug interaction is higher with cardiac drugs[16] 
and there are reports on potential DDIs in cardiology 
department from India.[17] There are no studies reporting 
actual incidence of DDIs in the Indian setting. Hence, 
the present study was designed to assess the incidence 
and pattern of DDIs in hospitalized cardiac patients in 
a tertiary care hospital, with the assessment of reaction 
characteristics, outcome and causality.
MATERIALS AND METHODS
Study design, population and data collection
A prospective observational study was carried out for a 
period of 3 months (April–July 2009) in a tertiary care 
teaching hospital. Ethical approval was obtained from 
Institutional ethics committee prior to initiation of the 
study (UEC/19/2009). Patients who were admitted 
consecutively to cardiology unit were included in the study. 
Prescriptions with two or more drugs prescribed during the 
hospitalization were only selected for the study. The study 
population comprised all patients aged 18 years or older 
admitted to the hospital and had a length of stay greater 
than 24 hours. Patients referred to the cardiology unit for 
evaluation, patients visiting on outpatient basis and patients 
who died during hospital stay were excluded from the study. 
Demographic information (age and gender), number of 
drugs taken, length of hospital stay, main diagnosis (ICD‑10) 
and the number of additional diagnoses and laboratory 
investigations made were obtained from the clinical records.
All the prescriptions of the study population were 
screened for DDIs by using computerized DDI database 
system.[18] For determining the ADRs, both the medications 
added and as well as discontinued were considered. All 
drugs were classified as per Anatomical Therapeutic 
Chemical Classification (ATC code, level one).[19] Certain 
demographic characteristics were studied to find out the 
predictors of DDIs, such as patient characteristics [gender, 
age (more than 18 years old), concurrent morbidities and 
length of stay], drug characteristic (number of drugs) 
and laboratory investigations [International Normalized 
Ratio (INR), bleeding time, serum creatinine and serum 
potassium level].
The patient’s medical records were screened for the presence 
of ADRs and the numbers of DDIs were calculated from 
the total number of DDIs. To classify the causality of the 
hospital admission to the drug, the Naranjo algorithm 
was used. The Naranjo algorithm or Naranjo Scale is a 
questionnaire designed by Naranjo et al., for determining the 
likelihood of whether an ADR is actually due to the drug 
rather than the result of other factors. Probability is assigned 
via a score termed definite, probable, possible or doubtful. 
Values obtained from this algorithm are sometimes used in 
peer reviews to verify the validity of author's conclusions 
regarding ADRs.[20] The interactions observed were classified 
into mild, moderate and severe according to severity and 
undesirable effects. The data on severity was obtained from 
the DDI data of the drug database.[18]
Statistical analysis
Frequencies with percentage were used to summarize 
sex, diagnosis, number of drugs dispensed, frequency 
of DDIs, drugs involved in the DDIs and severity of 
DDIs. Mean with 95% confidence interval was used to 
summarize age and length of stay. Chi‑square test was 
used to find the association between sex, number of drugs 
and DDIs. Spearman’s correlation was used to find the 
correlation between numbers of drugs, length of stay with 
DDIs. A “P” value of <0.05 was considered statistically 
significant. All analyses were performed using SPSS v. 15.
RESULTS
Patients, drug characteristics and DDIs
A total of 600 prescriptions were analyzed during the study 
period and it was found that 88 patients were confirmed with 
minimum of one DDI (14.66%). A significant proportion 
of patients with DDIs was females numbering 50 (56.82%), 
followed by males [38 (43.18%)]. The age group of more 
than 60 years had 51 (57.96%) DDIs, and was followed 
by other age groups. Patients who had taken more than 
10 drugs developed higher number of DDIs [58 (65.91%)]. 
Patient characteristics and statistical significance of the 
results are summarized in Table 1. The patients who stayed Mateti, et al.: Drug-drug interactions in hospitalized cardiac patients
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for 5–10 days developed DDIs more frequently than other 
groups [48 (54.55%)]. On an average, each patient had 3 
coded diagnosis in which anterior wall myocardial infarction 
was the most common condition [16 (18.18%)], followed 
by inferior wall myocardial infarction [14 (15.91%)], atrial 
fibrillation [9 (10.23%)], hypertension [4 (04.54%] and 
others [45 (51.14%)]. The most common drug classes 
involved in ADRs were the anti‑platelets [67 (76.13%)] and 
anticoagulant drugs [64 (72.72%)]. Heparin [55 (62.25%)] 
and aspirin [42 (47.72%)] were the most common drugs 
responsible for DDIs. Clinically important DDIs among 
the prescribed drugs are summarized in Table 2. Bleeding 
was the commonest clinical consequence in 76 (86.63%) 
cases. Clinical consequences of DDIs are summarized in 
Table 3. The data evaluated for the specific systems affected 
by DDIs are summarized in Table 4.
Causality and severity of DDIs
All of the DDIs were assessed to have the “probable” 
causality by using Naranjo algorithm. The interacting drugs 
were withdrawn in 70 cases (79.54%) and dose was altered 
in 12 cases (13.63%). Sixty (68.18%) patients improved 
after withdrawal of interacting drugs. Rechallenge was 
performed in 65 patients and recurrence of symptoms 
occurred in 8 patients. Upon causality assessment, majority 
of the DDI reports were rated as probable [46 (52.27%)] 
followed by possible rating for 24 (27.27%) reports. These 
DDIs were assessed for severity in which 54 cases (61.36%) 
were classified as moderate followed by 33 severe cases 
(37.50%) and 1 mild case (1.14%).
DISCUSSION
This study revealed the overall incidence of clinically 
important DDIs in cardiology department to be 14.66%. 
The incidence compared with another study published 
from the same setting on potential DDIs which reported 
an incidence of about 30%. This study focused on the 
incidence of actual DDIs compared to the reported study 
on potential DDIs which was about the possible DDIs 
which may arise out of the given combination.[17] Findings 
Table 1: Patient characteristics
Patient 
characteristics
Number (%) 
of ADRs
P value
Gender group 
Male
Female
 
38 (43.18)
50 (56.82)
 
χ2=12.69, 
df=3, P<0.05
Age (years)
<45
45–60
>60
 
10 (11.36)
27 (30.68)
51 (57.96)
 
χ2=15.23, 
df=3, 
P<0.05
No of drugs taken 
<5
5–10
>10
 
1 (1.14)
29 (32.95)
58 (65.91)
 
χ2=11.98, 
df=3, 
P<0.05
Table 2: Clinically important DDIs among the 
prescribed drugs
Objective drug Precipitant drug (n, %) Clinical consequences
Heparin
C05BA03
Aspirin (33, 37.54%)
B01AC06
Streptokinase (3, 3.40%)
B01AD01
Warfarin (8, 9.09%)
B01AA03
Bleeding 
Bleeding↓
Bleeding
Aspirin
B01AC06
Diltiazam (3, 3.40%)
C08DB01
Eptifibatide (1, 1.13%)
B01AC16
Insulin (1, 1.13%)
A10AE01
Captopril (1, 1.13%)
C09AA01
Furosemide (1, 1.13%)
C03CA01
Bleeding↑
Bleeding 
Hypoglycemia
Captopril effect↓
Furosemide effect ↓
Warfarin
B01AA03
Clopidogrel (2, 2.27%)
B01AC04
Amoxicillin (1, 1.13%)
J01CR02
Aspirin (1, 1.13%)
B01AC06
Atenolol (1, 1.13%)
C07AB03
Phenytoin (1, 1.13%)
N03AB02
Bleeding
 
Bleeding
 
Bleeding
 
Bleeding
 
Bleeding
Clopidogrel
B01AC04
Heparin (11, 12.5%)
C05BA03
Torsemide (11, 12.5%)
C03CA04
Enoxaparin (8, 9.09%)
B01AB05
Aspirin (1, 1.13%)
B01AC06
Bleeding 
Torsemide toxicity
Bleeding
 
Bleeding
↓ ‑ decrease, ↑‑ increase
Table 3: Clinical consequences of DDIs
Clinical consequences No. of DDIs (%)
Bleeding
Torsemide toxicity
Hypoglycemia
Furosemide effect ↓
Captopril effect ↓
76 (86.63)
11 (12.50)
01 (01.13)
01 (01.13)
01 (01.13)
↓ ‑ decrease, DDI ‑ Drug–drug interactions
Table 4: Organ systems affected by the DDIs
Organ system Documented 
complications of DDIs
Number (%)
Platelet, bleeding and 
clotting disorders
Bleeding 76 (86.63)
Body as a whole – 
General disorders
Therapeutic effect 
increased (drug toxicity)
11 (12.50)
Heart rate and rhythm 
disorders
Bradycardia 9 (2.31)
Urinary system 
disorders
Acute renal failure 5 (1.28)
Central and peripheral 
nervous system disorder
Headache 2 (0.51)Mateti, et al.: Drug-drug interactions in hospitalized cardiac patients
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of the present study showed that the patterns of incidence 
of DDIs are positively associated with patients’ age, gender, 
number of drugs prescribed and length of hospital stay. 
A higher rate of DDI was present in women and patients 
who were more than 60 years of age. This corresponds to 
results of other studies reporting that DDIs are common 
in elderly people who are on multiple drug regimens.[6,21,22] 
The results showed that higher rate of DDIs seen in 
elderly patients was due to the increased number of 
medications prescribed to this population. These results are 
in accordance with the observation of reported studies.[23] 
Positive association was observed between the number of 
drugs prescribed and length of stay with DDIs.
In fact, some of these drug combinations are used for 
therapeutic benefit in clinical practice and others are 
introduced internationally despite the increased risk of 
DDIs. Some of the most common drug classes involved 
in DDIs were anti‑platelets (76.13%) and anticoagulants 
(72.72%). Among these drug classes, heparin and aspirin 
(37.54%), clopidogrel and heparin (12.5%), clopidogrel 
and torsemide (12.5%) and heparin and warfarin 
(9.09%) were the most commonly observed drug pairs 
resulting in DDIs, and bleeding was the most common 
clinical consequence observed in the present study. This 
result correlates with the results of similar studies.[24] 
In 2006, the NPSA risk assessment of anticoagulation 
therapy highlighted co‑prescribing of nonsteroidal anti‑
inflammatory drugs (NSAIDs) and other interacting 
medicines in anticoagulated patients as one of 15 key high‑
risk prescribing practices.[25] The potential consequences 
of such prescribing practice are an increase in the risk of 
bleeding complications, which have been reported to affect 
between 7 and 26% of warfarinized patients annually. Of 
these bleeds, 6–15% were reported to be minor, 1–8% were 
major, and 0.25–4.8% were fatal.[26,27] 
Caution must be exercised in comparing the exact rates of 
each DDI by maintaining the normal range of activated 
partial thromboplastin time (aPTT) and INR value 
because even slight increase or decrease in plasma drug 
concentration can have profound clinical effects. On the 
other hand, for this same reason, patients using heparin 
and warfarin are often subject to rigorous monitoring of 
aPTT or INR and doses might be adjusted according to 
lab reports.
DDIs were reported from cardiology department. 
Concurrent use of many drugs and frequent addition 
of new drugs makes this group of patients vulnerable 
to DDIs. Despite all this, there is a need to increase the 
awareness of possible DDIs in all hospital departments, 
as a sizeable number of DDIs have been recorded in all 
of them. The age, gender, number of drugs taken and 
multiple disease states were identified as the risk factors 
for developing DDIs (P<0.0001). There was an extremely 
significant linear relationship (r=0.98; P<0.01) between 
the number of drugs prescribed and the DDIs in patients. 
Similarly, a significant linear relationship (r=0.96; P<0.0001) 
was observed between length of stay and DDIs. These 
results are in accordance with previous reports available 
in the literature.[28] 
Consistent with previous research, it was observed in this 
study that the use of multiple medications was associated 
with significantly increased risk of being prescribed 
potentially harmful drug–drug combinations; in fact, the 
odds of being prescribed potentially interacting drug more 
than doubled for each additional medication prescribed, 
after controlling for other factors.[29,30] With regard to 
management approach for DDIs, drug withdrawal or 
dose reduction is usually the first step to be employed for 
the management of DDIs. In present study, in 70 cases 
(79.54%) the suspected drug was withdrawn, and in 
12 (13.63%) cases the dose of the suspected drug was 
altered. Drug withdrawals and dose alterations of suspected 
drugs have been reported in the literature.[25] 
On causality assessment of DDIs by using Naranjo 
algorithm, DDIs were confirmed to have the probable 
causality. Considering the severity assessment of the 
reactions, majority of the reactions were categorized as 
moderate in nature, followed by severe and mild severity, 
and these findings are different when compared with the 
reports of spontaneous reporting studies.[21,31]
The usefulness of computerized screening depends on 
the quality, including proper validation, of data held in the 
software. Furthermore, updating such systems requires 
knowledge, judgment and continuous effort by specialists 
maintaining the drug interaction database.[31]
Limitation of this study is its short duration without any 
intervention component. Controlled study to evaluate 
whether good clinical management of DDIs can reduce 
drug‑related morbidity or mortality is needed in the future 
in this discipline. 
CONCLUSION
This study reports the incidence of DDIs in the cardiology 
department in a hospital from Indian setting. This study 
also examined patient, drug characteristics, causality and Mateti, et al.: Drug-drug interactions in hospitalized cardiac patients
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severity of DDIs. This study shows that DDIs are frequent 
among hospitalized cardiac patients. The factors influencing 
DDIs are age, gender, number of prescribed drugs and 
length of hospital stay and cost. Thus, development and 
implementation of cautionary guidelines and computer‑
based screening might help to prevent potentially harmful 
drug interactions.
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